再鼎医药盘中股价曾一度大跌5.21%,引发市场广泛关注。
公司于最新公布的2024年全年业绩显示,按美国公认会计准则,年度净亏损收窄至2.57亿美元,较2023年3.35亿美元的亏损有所改善,但仍处于亏损状态。全年总收入达3.99亿美元,同比增长49.6%,主要得益于艾加莫德和则乐、纽再乐销售收入持续增长。
值得注意的是, 2025年公司全年收入指引介乎5.6亿至5.9亿美元,相比去年增幅放缓;而公司预期到2025年第四季度方能实现非美国公认会计准则经营利润转亏为盈。或许是业绩持续亏损以及增长预期不达预期,令投资者对该公司前景失去信心,导致盘中股价大跌。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.